🟢 Immix Biopharma is trading 8% up in pre-market with no clear company-specific catalyst

Immix Biopharma is trading at $9.00, up +7.78%, before the October 23, 2026 open, with no clear company-specific announcement tied to the move.

• The latest company news found was an October 5 conference announcement.
• Morgan Stanley raised its price target to $20 from $19 on October 20; available reporting does not connect the increase directly to the pre-market rise.